Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 10.66
-0.35 (-3.18%)
Nov 13, 2026, 3:04 PM CST
SHE:301211 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 481.33 | 445.8 | 437.76 | 651.42 | 511.65 | 539.75 |
Other Revenue | 7.5 | 7.5 | 8.11 | 11.61 | 3.26 | 0.87 |
| 488.84 | 453.31 | 445.86 | 663.03 | 514.91 | 540.62 | |
Revenue Growth | 13.48% | 1.67% | -32.75% | 28.77% | -4.76% | -8.82% |
Cost of Revenue | 377.19 | 358.41 | 317.79 | 397.55 | 369.78 | 358.33 |
Gross Profit | 111.64 | 94.9 | 128.07 | 265.47 | 145.13 | 182.3 |
Selling, General & Admin | 65.29 | 64.55 | 61.71 | 62.09 | 47.9 | 38.54 |
Research & Development | 23.92 | 25.18 | 32.94 | 52.77 | 19.84 | 18.28 |
Other Operating Expenses | 7.18 | 5.24 | 3.77 | 5.92 | 3.96 | 5.89 |
Operating Expenses | 96.44 | 95.09 | 98.44 | 120.07 | 69.78 | 64.23 |
Operating Income | 15.2 | -0.19 | 29.64 | 145.4 | 75.35 | 118.06 |
Interest Expense | -0.12 | -0.18 | -0.31 | -0.31 | -0.34 | - |
Interest & Investment Income | 21.04 | 28.11 | 51.33 | 47.84 | 61.02 | 13.1 |
Currency Exchange Gain (Loss) | -1.55 | -1.55 | 3.34 | 3.36 | 4.78 | -3.62 |
Other Non Operating Income (Expenses) | -3.73 | -0.45 | -0.63 | -0.39 | -0.44 | 0.13 |
EBT Excluding Unusual Items | 30.85 | 25.74 | 83.36 | 195.9 | 140.36 | 127.68 |
Gain (Loss) on Sale of Investments | 18.26 | 12.97 | 14.58 | 4.02 | - | - |
Gain (Loss) on Sale of Assets | -0 | 0.01 | - | 0.18 | 0.04 | -0.07 |
Asset Writedown | 2.01 | -0.02 | -0.11 | -2.58 | -0.66 | -0 |
Other Unusual Items | 9.84 | 2.56 | 2.58 | 5.3 | 7.69 | 11.58 |
Pretax Income | 60.97 | 41.26 | 100.42 | 202.82 | 147.44 | 139.18 |
Income Tax Expense | 7.33 | 6.35 | 8.87 | 26.7 | 21.65 | 17.54 |
Earnings From Continuing Operations | 53.64 | 34.91 | 91.55 | 176.12 | 125.79 | 121.65 |
Net Income | 53.64 | 34.91 | 91.55 | 176.12 | 125.79 | 121.65 |
Net Income to Common | 53.64 | 34.91 | 91.55 | 176.12 | 125.79 | 121.65 |
Net Income Growth | 41.82% | -61.87% | -48.02% | 40.01% | 3.41% | -27.62% |
Shares Outstanding (Basic) | 453 | 436 | 416 | 419 | 415 | 311 |
Shares Outstanding (Diluted) | 453 | 436 | 416 | 419 | 415 | 311 |
Shares Change | 8.07% | 4.87% | -0.60% | 0.97% | 33.19% | -1.01% |
EPS (Basic) | 0.12 | 0.08 | 0.22 | 0.42 | 0.30 | 0.39 |
EPS (Diluted) | 0.12 | 0.08 | 0.22 | 0.42 | 0.30 | 0.39 |
EPS Growth | 31.23% | -63.64% | -47.71% | 38.66% | -22.36% | -26.88% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -55.51 | -44.78 | -68.36 | -49.47 | 174.84 | 102.92 |
Free Cash Flow Per Share | -0.12 | -0.10 | -0.16 | -0.12 | 0.42 | 0.33 |
Dividend Per Share | 0.060 | 0.060 | 0.250 | 0.331 | 0.230 | 0.172 |
Dividend Growth | -76.00% | -76.00% | -24.47% | 43.98% | 33.35% | - |
Gross Margin | 22.84% | 20.93% | 28.73% | 40.04% | 28.18% | 33.72% |
Operating Margin | 3.11% | -0.04% | 6.65% | 21.93% | 14.63% | 21.84% |
Profit Margin | 10.97% | 7.70% | 20.53% | 26.56% | 24.43% | 22.50% |
Free Cash Flow Margin | -11.36% | -9.88% | -15.33% | -7.46% | 33.96% | 19.04% |
EBITDA | 71.01 | 42 | 53.68 | 165.63 | 95.73 | 137.43 |
EBITDA Margin | 14.53% | 9.26% | 12.04% | 24.98% | 18.59% | 25.42% |
D&A For EBITDA | 55.8 | 42.19 | 24.05 | 20.23 | 20.38 | 19.37 |
EBIT | 15.2 | -0.19 | 29.64 | 145.4 | 75.35 | 118.06 |
EBIT Margin | 3.11% | -0.04% | 6.65% | 21.93% | 14.63% | 21.84% |
Effective Tax Rate | 12.03% | 15.39% | 8.83% | 13.16% | 14.68% | 12.60% |
Revenue as Reported | 488.84 | 453.31 | 445.86 | 663.03 | 514.91 | 540.62 |